US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas.
According to the report, Morningstar believes the market is under-appreciating the significance of innovation in the biopharma industry, and forecast 4.5% compound annual earnings growth in the sector over the next five years (excluding COVID products).
Additional takeaways include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze